Bluebird Bio Inc. (BLUE) Trading Down 2.2%
Shares of Bluebird Bio Inc. (NASDAQ:BLUE) fell 2.2% during trading on Thursday . The stock traded as low as $48.54 and last traded at $49.13, with a volume of 876,687 shares trading hands. The stock had previously closed at $50.26.
Several brokerages have commented on BLUE. Wells Fargo & Co. reiterated a “buy” rating on shares of Bluebird Bio in a research report on Thursday, May 5th. Goldman Sachs Group Inc. reiterated a “buy” rating and set a $135.00 target price on shares of Bluebird Bio in a research report on Thursday, August 18th. Wedbush reiterated an “outperform” rating and set a $117.00 target price on shares of Bluebird Bio in a research report on Thursday, May 5th. Zacks Investment Research upgraded shares of Bluebird Bio from a “sell” rating to a “hold” rating in a research report on Monday, August 8th. Finally, BTIG Research reiterated a “buy” rating and set a $72.00 target price on shares of Bluebird Bio in a research report on Wednesday, June 29th. Six analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $82.50.
The company has a 50-day moving average price of $52.56 and a 200-day moving average price of $46.99. The firm’s market capitalization is $1.86 billion.
Bluebird Bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, August 3rd. The company reported ($1.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.15. The firm earned $1.55 million during the quarter, compared to the consensus estimate of $2.01 million. During the same period in the previous year, the company posted ($1.57) EPS. Bluebird Bio’s revenue for the quarter was down 68.6% compared to the same quarter last year. Analysts anticipate that Bluebird Bio Inc. will post ($6.14) earnings per share for the current year.
In other Bluebird Bio news, insider David Davidson sold 1,000 shares of Bluebird Bio stock in a transaction dated Wednesday, June 15th. The stock was sold at an average price of $40.11, for a total transaction of $40,110.00. Following the completion of the transaction, the insider now owns 10,600 shares in the company, valued at approximately $425,166. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Philip D. Gregory sold 2,931 shares of Bluebird Bio stock in a transaction dated Thursday, June 16th. The shares were sold at an average price of $39.52, for a total value of $115,833.12. Following the transaction, the insider now owns 30,069 shares of the company’s stock, valued at approximately $1,188,326.88. The disclosure for this sale can be found here.
A number of institutional investors recently added to or reduced their stakes in the stock. RS Investment Management Co. LLC increased its position in Bluebird Bio by 91.6% in the fourth quarter. RS Investment Management Co. LLC now owns 515,846 shares of the company’s stock worth $33,128,000 after buying an additional 246,622 shares during the period. State of Tennessee Treasury Department increased its position in Bluebird Bio by 45.4% in the fourth quarter. State of Tennessee Treasury Department now owns 191,963 shares of the company’s stock worth $12,328,000 after buying an additional 59,952 shares during the period. Dimensional Fund Advisors LP increased its position in Bluebird Bio by 6.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 74,831 shares of the company’s stock worth $4,806,000 after buying an additional 4,454 shares during the period. Finally, Jennison Associates LLC increased its position in Bluebird Bio by 171.3% in the fourth quarter. Jennison Associates LLC now owns 864,314 shares of the company’s stock worth $55,506,000 after buying an additional 545,727 shares during the period.
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.